AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03647176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold snare polypectomy
Description: cold snare polypectomy (CSP), which does not include electrocautery to do a polypectomy with a snare
Study NCT00399568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo 100 mL solution
Description: IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
Study NCT01634113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium-bromide
Description: IMP
Study NCT01634113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching tiotropium
Study NCT02979444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Groups
Description: The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood.
Study NCT03432572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridium
Description: a urine discoloration agent
Study NCT03432572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: a urine discoloration agent
Study NCT03432572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiamine
Description: active placebo not known to cause urine discoloration
Study NCT01033604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glyaderm and split skin graft
Description: Full thickness defects treated with Glyaderm and split skin graft.
Study NCT01033604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split skin graft alone.
Description: Full thickness defects treated with split skin graft alone.
Study NCT01993667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Acetazolamide
Description: Administration of low dose acetazolamide
Study NCT01993667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Dose Acetazolamide
Description: Administration of normal dose acetazolamide
Study NCT01807767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus, Myfortic and Tacrolimus
Description: Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID
Study NCT01807767 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Myfortic and Tacrolimus
Description: Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
Study NCT01318668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccination with Nicvax
Description: 5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
Study NCT02552667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1102+HGP0711Placebo
Description: Coadministration of HCP1102 with HGP0711 Placebo for 4-week
Study NCT02552667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1102Placebo+HGP0711
Description: Coadministration of HCP1102 Placebo with HGP0711 for 4-week
Study NCT00600275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGT226
Study NCT02424500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: d-Nav
Description: Insulin dosage is adjusted as required
Study NCT02424500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Glucose Monitoring System
Description: Insulin dosage is adjusted as required
Study NCT01061723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT01061723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT01061723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT01680354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ReLEx
Study NCT01680354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Study NCT04354948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain (hypertonic saline)
Description: A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
Study NCT04354948 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No pain (Hypotonic saline)
Description: A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
Study NCT02476032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prof applied oxalate
Description: Crest Sensi-Stop strips (Procter \& Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
Study NCT02476032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self applied oxalate
Description: Subjects will apply the strips (Procter \& Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
Study NCT03621189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol
Study NCT03621189 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol
Study NCT03483831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.
Study NCT04822311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Investigate the effects of an exercise intervention on retired APF players
Description: Enrolled participants will perform a 18 months exercise intervention which involves 90 exercise rehabilitation training visits. In addition, participants will also be tested on various measures of health and function both at baseline (prior to intervention), at 6 months, 12 months, and 18 months (post intervention).
Study NCT02468141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJDBT
Description: Sipjeondaebo-tang
Study NCT02468141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00580021 — intervention group
Intervention type: OTHER
Intervention: Genotyping
Description: Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
Study NCT03126279 — intervention group
Intervention type: PROCEDURE
Intervention: Total Knee Replacement Surgery
Description: All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
Study NCT01569087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: empegfilrastim
Description: Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.
Study NCT01569087 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
Study NCT02476032 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Prof applied placebo
Description: Crest Sensi-Stop strips (Procter \& Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
Study NCT03836872 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
Study NCT03836872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
Study NCT00699946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
Study NCT00699946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
Study NCT01498744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Clindamycin
Description: Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
Study NCT03308968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm.
Study NCT03308968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm.
Study NCT03308968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Study NCT03308968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Study NCT04148053 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TB-antigen responsive T cell markers
Description: A blood test including a series of T cell markers which are responsive to TB antigens
Study NCT01265368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGN1601
Description: Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
Study NCT02330536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insufflation of carbon dioxide (CO2)
Description: After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
Study NCT03777254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC28-E
Description: RC28-E intravitreous injection 50ul
Study NCT03346421 — intervention group
Intervention type: BEHAVIORAL
Intervention: diet and physical activity
Study NCT02853396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy
Study NCT02853396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Study NCT04583436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular recanalization
Description: Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
Study NCT04583436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
Study NCT03281031 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Additional MRI Examination
Description: MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
Study NCT01175876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote limb ischemic preconditioning
Description: Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
Study NCT01175876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting is an invasive therapy of carotid stenosis.
Study NCT01175876 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting is an invasive therapy of carotid stenosis.
Study NCT00812396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: low dose testosterone
Description: Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
Study NCT00812396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: high dose testosterone
Description: Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
Study NCT00812396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
Study NCT01067118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LINjeta U-100 Insulin
Description: LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
Study NCT01067118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog U-100
Description: Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
Study NCT03150550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Description: Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.
Study NCT03150550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse prevention
Description: It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
Study NCT02998684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation
Study NCT02998684 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Study NCT02998684 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PEERS Social Skills Training
Description: 14 weekly social skills training sessions for all participants
Study NCT02998684 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: PEERS Social Skills Training
Description: 14 weekly social skills training sessions for all participants
Study NCT03293290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP
Description: Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
Study NCT00653575 — intervention group
Intervention type: BEHAVIORAL
Intervention: Information-Motivation-Behavioral Skills model
Description: The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
Study NCT02735057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT04512677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Timed Inspiratory Effort (TIE index)
Description: Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
Study NCT03979469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine, dexmedetomidine
Description: Patients will receive non-opioid analgesics, such as dexmedetomidine, ketamine perioperatively
Study NCT03979469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl, remifentanil
Description: Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
Study NCT03080571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous BMMNC stem cells
Description: Autologous BMMNC injected in the ipsilateral MCA
Study NCT03080571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Study NCT03080571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Study NCT01050023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provant Device (Wound Therapy System)
Description: Twice daily application of the active Provant device to the wound for twelve (12) weeks.
Study NCT01050023 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Provant Device - Inactive
Description: Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
Study NCT02110433 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo group
Description: patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations